ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO333

Challenges in Identifying and Managing Lithium-Induced Arginine-Vasopressin Resistance

Session Information

Category: Fluid, Electrolytes, and Acid-Base Disorders

  • 1102 Fluid, Electrolyte, and Acid-Base Disorders: Clinical

Authors

  • Neuman, Michelle, West Virginia University, Morgantown, West Virginia, United States
  • Bradner, Abigail, West Virginia University, Morgantown, West Virginia, United States
  • Bergeron, Jennifer, West Virginia University, Morgantown, West Virginia, United States
Introduction

Arginine vasopressin resistance (AVP-R), formerly nephrogenic diabetes insipidus, is the inability to concentrate urine due to resistance to AVP. Lithium is a classic cause of AVP-R, but identifying and managing AVP-R is not always textbook. In this case of AVP-R in lithium toxicity, UTI and dysphagia significantly delayed the diagnosis and improvement in symptoms.

Case Description

A 71-year-old female with bipolar disorder on chronic lithium, CKD3, and hypertension was admitted for 1 week of confusion, vomiting, and diarrhea. Labs were remarkable for creatinine 3.3mg/dL and sodium 133mEq/L (1 year ago 1.2 and 141 respectively). UA showed a UTI, which was presumed to be the cause of her symptoms. She was given fluids and her Cr improved to 2.5mg/dL. The case seemed closed.
Surprisingly, the next day, her sodium was 154mEq/L with >3.5L urine output. Urine osmolality (UOsm) was 189mOsm/kg consistent with water diuresis, triggering a lithium level to be sent. It was 1.92mEq/L, consistent with lithium toxicity given her symptoms. Lithium was held and Nephrology conducted a desmopressin challenge without improvement in her Uosm, confirming AVP-R.
She was given ample free water. Despite 5 days without lithium, her UOsm fell to 79mOsm/kg. With amiloride daily, Uosm rose to 137mOm/kg, but for days her sodium continued to fluctuate. HCTZ did not help. Eventually, we noted that she had a thickened liquids diet. The thickener is 5.5g modified food starch with 15mg of sodium in 4oz water. Once she was cleared for thin liquids, her sodium stabilized at 142mEq/L. Unfortunately, 11 days later she continued to have neuro symptoms, requiring inpatient rehab discharge for Syndrome of Irreversible Lithium-Effectuated NeuroToxicity (SILENT).

Discussion

This case reveals that lithium induced AVP-R can be masked by volume depletion from UTI and gives evidence that AVP-R can manifest quickly and worsen even after lithium is stopped. Furthermore, it demonstrates how lithium neurotoxicity complicates achieving euvolemia and free water and low solute/protein intake. We found that thickeners add tonicity (and aversion) to otherwise good fluid intake. This case demonstrates the importance of prompt diagnosis and multi-faceted management of lithium toxicities to prevent prolonged hospitalization and permanent life-altering neuromuscular symptoms.